Great news, finally.
I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.
I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?
If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.
Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...
If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?
Cheers
- Forums
- ASX - By Stock
- CGS
- Putting numbers on it
Putting numbers on it
-
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.020(1.70%) |
Mkt cap ! $197.2M |
Open | High | Low | Value | Volume |
$1.18 | $1.19 | $1.15 | $101.3K | 87.10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15135 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 5670 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15135 | 1.155 |
1 | 9276 | 1.150 |
1 | 9403 | 1.130 |
2 | 4417 | 1.090 |
1 | 2000 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
1.185 | 3899 | 1 |
1.200 | 3000 | 1 |
1.235 | 3267 | 1 |
1.250 | 7975 | 2 |
1.285 | 10501 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
CGS (ASX) Chart |